Browse Catapults

News from the catapult network

News headlines from across the Catapult Network. For comprehensive news updates, please explore our Politics Home webpage or visit individual Catapult websites

Graphic of four images including a microscope, a solar panel, a man examining a samply and a flying drone
Catapult Network
NEWS
Catapulting growth in 2023 and beyond
In the face of many challenges – changing customer desires, cost pressures, supply chain disruption, expected regulatory changes and fierce competition – UK innovation is on the rise. This article showcases how Catapults helped to deliver great results for business and industry in 2023; it summarises our predictions for technology-driven advances in 2024 and the years ahead.
Read more
Medicines Discovery
alt=
News
New Gene Editing License Agreement Set to Unlock Deeper Drug Discovery Insights
ERS Genomics Limited (ERS), the CRISPR licensing Company, and Medicines Discovery Catapult have signed a commercial-use CRISPR license agreement. The partnership combines ERS’s CRISPR/Cas9 patent portfolio with MDC’s world-class expertise and technology. This is significant news for those involved in preclinical research, as it extends Medicines Discovery Catapult’s ability to help create breakthrough products and services that will help de-risk them, drive sector productivity, and attract investment.
Read more
Medicines Discovery
News
New Gene Editing License Agreement Set to Unlock Deeper Drug Discovery Insights
ERS Genomics Limited (ERS), the CRISPR licensing Company, and Medicines Discovery Catapult have signed a commercial-use CRISPR license agreement. The partnership combines ERS’s CRISPR/Cas9 patent portfolio with MDC’s world-class expertise and technology. This is significant news for those involved in preclinical research, as it extends Medicines Discovery Catapult’s ability to help create breakthrough products and services that will help de-risk them, drive sector productivity, and attract investment.
Read more
Medicines Discovery
Graphic for Medicines Discovery Catapult's annual report
News
Medicines Discovery Catapult Annual Report Published, For the Year Ended 31 March 2024
Medicines Discovery Catapult Limited’s Annual Report for the year ended 31 March 2024 is now published. The Financial Year 2023/24 was highly challenging for international biotech. It saw a 50% decline in venture capital funding, driven by global economic forces and also – in the UK – a rise in operating costs, driven by inflation and the scarcity of key resources in skills and space. This Annual Report shows that despite this challenging economic background, Medicines Discovery Catapult’s overall contribution to medicines discovery in the UK continues to grow.
Read more